Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Intangibles (2016 - 2026)

Usana Health Sciences has reported Intangibles over the past 16 years, most recently at $128.9 million for Q2 2026.

  • Quarterly Intangibles fell 12.41% to $128.9 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $128.9 million through Apr 2026, down 12.41% year-over-year, with the annual reading at $133.2 million for FY2026, 12.3% down from the prior year.
  • Intangibles was $128.9 million for Q2 2026 at Usana Health Sciences, down from $133.2 million in the prior quarter.
  • Over five years, Intangibles peaked at $151.8 million in Q4 2024 and troughed at $28.6 million in Q2 2024.
  • The 5-year median for Intangibles is $32.1 million (2022), against an average of $67.2 million.
  • Year-over-year, Intangibles fell 25.67% in 2022 and then skyrocketed 407.45% in 2024.
  • A 5-year view of Intangibles shows it stood at $32.4 million in 2022, then fell by 7.75% to $29.9 million in 2023, then skyrocketed by 407.45% to $151.8 million in 2024, then decreased by 9.0% to $138.2 million in 2025, then fell by 6.7% to $128.9 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Intangibles are $128.9 million (Q2 2026), $133.2 million (Q1 2026), and $138.2 million (Q3 2025).